Gene expression profiles of oral soft tissue‐derived fibroblast from healing wounds: correlation with clinical outcome, autophagy activation and fibrotic markers expression

Expression of Basophil Activation Markers in Pediatric Asthma

Background: Asthma is very common in children and its diagnosis is based on clinical manifestations, which can be misdiagnosed as other respiratory diseases with similar signs and symptoms. Objective: To analyze the expression of ST2L and CD203c in the diagnosis of pediatric asthma. Methods: Basophils were purified from whole blood samples of patients and healthy controls using Ficol-Paque grad...

Induced expression of syndecan in healing wounds

We have studied the expression of an integral cell surface proteoglycan, syndecan, during the healing of cutaneous wounds, using immunohistochemical and in situ hybridization methods. In normal mouse skin, both syndecan antigen and mRNA were found to be expressed exclusively by epidermal and hair follicle cells. After incision and subsequent suturing, remarkably increased amounts of syndecan on...

The Expression of The Autophagy Gene Beclin-1 mRNA and Protein in Ectopic and Eutopic Endometrium of Patients with Endometriosis

Correlation of EGFR Expression with Survival Rate in Patients with Oral Squamous Cell Carcinoma

Background and Aim: This study aimed to indicate the role of epidermal growth factor (EGF) in proliferation and growth of epithelial tissue and to determine the correlation be-tween the frequency of expression of EGF receptor (EGFR) by means of immunohistochemistry with survival rate in oral squamous cell carcinoma (OSCC). Materials and Methods: Thirty-eight cases of OSCC diagnosed by hemato...

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

The aims of this study were to assess the feasibility of prospective pharmacogenomics research in multicenter international clinical trials of bortezomib in multiple myeloma and to develop predictive classifiers of response and survival with bortezomib. Patients with relapsed myeloma enrolled in phase 2 and phase 3 clinical trials of bortezomib and consented to genomic analyses of pretreatment ...